Full-text resources of CEJSH and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

Refine search results

Journals help

  1. 1 Kontrola Państwowa

Authors help

  1. 1 Nosal D.

  2. 1 Wasilewski P.

Years help

  1. 1 2022

Results found: 1

first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  Arechin
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Nieskuteczny nadzór nad lekami - dopuszczanie, zmiany porejestracyjne i kontrola obrotu

100%
Nosal D., Wasilewski P.
Kontrola Państwowa
|
2022
|
vol. 67
|
issue 3 (404)
117-127
EN
In 2021, the Supreme Audit Office, taking into account the findings of a previous ad hoc audit, conducted the audit dedicated to registration of medicinal products and changes introduced following registration. The audit covered the years 2019–2021 (by 30 June) and focused on admitting to the market, as well as the safety of medicinal products admitted to the marked within the national procedure. Unlike in the European procedures, only Polish bodies – the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Product (URPL) and the Chief Pharmaceutical Inspectorate (GIF) – are responsible for admitting medicinal products to the market and for supervision of their production. Moreover, the audit examined the changes introduced after registration, consisting in adding new therapeutical indications for medicinal products. Since the state bodies perform their statutory tasks via the officials they employ, the Supreme Audit Office has examined whether the President of the URPL and the GIF provided appropriate organisational conditions to fulfil these tasks.
PL
Kupując lek zakładamy, że sprzedaż w aptece gwarantuje, iż procedura jego dopuszczania do obrotu przebiegła zgodnie z prawem, a produkt został rzetelnie przebadany. Uważamy, że jest bezpieczny i skuteczny w leczeniu określonych chorób lub w ich profilaktyce oraz wytwarzany, przechowywany i dystrybuowany w warunkach gwarantujących jego jakość. Poczucie bezpieczeństwa daje nam system nadzoru, obejmujący monitorowanie i kontrolowanie procesu dostarczania leku pacjentom. Jak w praktyce wykonywane są te zadania sprawdziła Najwyższa Izba Kontroli, podejmując kontrolę organów odpowiedzialnych za dopuszczanie do obrotu produktów leczniczych.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.